ID

35276

Description

A Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis; ODM derived from: https://clinicaltrials.gov/show/NCT02504294

Link

https://clinicaltrials.gov/show/NCT02504294

Keywords

  1. 2/26/19 2/26/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 26, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Chronic Kidney Disease (CKD) NCT02504294

Eligibility Chronic Kidney Disease (CKD) NCT02504294

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. adult female or male subjects; age ≥18 years.
Description

Adult | Age

Data type

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
2. end stage renal disease subjects treated in-center with the modality of hemodialysis for ≥120 days.
Description

Kidney Failure, Chronic | Hemodialysis

Data type

boolean

Alias
UMLS CUI [1]
C0022661
UMLS CUI [2]
C0019004
3. diagnosed with anemia.
Description

Anemia

Data type

boolean

Alias
UMLS CUI [1]
C0002871
4. administered routine epogen therapy for at least 16 weeks by an iv route for treatment of anemia using the epogen version of the fresenius medical care north america (fmcna) dosing algorithm for esa.
Description

Epogen Intravenous | Anemia | Unit dose Algorithm Erythropoiesis Stimulating Agents

Data type

boolean

Alias
UMLS CUI [1,1]
C0700704
UMLS CUI [1,2]
C1522726
UMLS CUI [2]
C0002871
UMLS CUI [3,1]
C0869039
UMLS CUI [3,2]
C0002045
UMLS CUI [3,3]
C1959590
5. currently using the iv epogen version of the esa dosing algorithm cmab 5 for anemia management.
Description

Epogen Intravenous | Unit dose Algorithm Erythropoiesis Stimulating Agents | Anemia Management

Data type

boolean

Alias
UMLS CUI [1,1]
C0700704
UMLS CUI [1,2]
C1522726
UMLS CUI [2,1]
C0869039
UMLS CUI [2,2]
C0002045
UMLS CUI [2,3]
C1959590
UMLS CUI [3,1]
C0002871
UMLS CUI [3,2]
C0376636
6. receiving hemodialysis at a clinic using the fmcna dosing algorithm for iv iron that is the fmcna standard of care for iron replacement.
Description

Hemodialysis | Iron replacement Intravenous | Unit dose Algorithm

Data type

boolean

Alias
UMLS CUI [1]
C0019004
UMLS CUI [2,1]
C0919650
UMLS CUI [2,2]
C1522726
UMLS CUI [3,1]
C0869039
UMLS CUI [3,2]
C0002045
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. subjects unable to provide a signed and dated informed consent for this clinical research study.
Description

Informed Consent Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C1299582
2. as determined by the investigator, female subjects of childbearing potential who do not agree to use a highly effective method of contraception.
Description

Childbearing Potential Contraceptive methods Unwilling

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
3. any condition as determined by the investigator that would place a subject at an increased risk, or preclude subject's full compliance with the study procedures and visits.
Description

Condition Study Subject Participation Status At risk | Condition Excludes Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1444641
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0332196
UMLS CUI [2,3]
C0525058
4. female subjects who are known to be or found to be, pregnant or lactating.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
5. subjects that are not a candidate for esa therapies per the label warnings listed in the package insert for epogen and/or contraindications to epoetin hospira listed in the investigators' brochure; or have had a known positive test for anti-rhepo antibodies.
Description

Study Subject Inappropriate Erythropoiesis Stimulating Agents | Epogen Package Inserts | Other Coding | Recombinant Erythropoietin Antibodies Positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C1959590
UMLS CUI [2,1]
C0700704
UMLS CUI [2,2]
C0030174
UMLS CUI [3]
C3846158
UMLS CUI [4,1]
C0376541
UMLS CUI [4,2]
C0003241
UMLS CUI [4,3]
C1514241
6. treatment with any investigational drug within 30 days prior to randomization and throughout this clinical trial.
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
7. diagnosed with any concurrent condition that could lead to greater-than-normal loss of blood, including but not limited to menorrhagia, peptic ulcer disease, gastrointestinal bleeding, blood dyscrasia, hemoglobinopathy, anticoagulation therapy (except when administered for the purpose of dialysis therapy and except aspirin (acetylsalicylic acid [asa] therapies)) etc.
Description

Condition Resulting in Blood Loss | Menorrhagia | Peptic Ulcer | Gastrointestinal Hemorrhage | Hematological Disease | Hemoglobinopathy | Anticoagulation Therapy | Exception Dialysis | Exception Aspirin therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0332294
UMLS CUI [1,3]
C3163616
UMLS CUI [2]
C0025323
UMLS CUI [3]
C0030920
UMLS CUI [4]
C0017181
UMLS CUI [5]
C0018939
UMLS CUI [6]
C0019045
UMLS CUI [7]
C0003281
UMLS CUI [8,1]
C1705847
UMLS CUI [8,2]
C0011946
UMLS CUI [9,1]
C1705847
UMLS CUI [9,2]
C4303556
8. history of transfusion of any blood product in the past 3 months, or 2 or more transfusions in the past 1 year; or donated or lost >475 ml blood volume (including plasmapheresis) in the past 3 months.
Description

Blood Transfusion Quantity | Blood Donation Amount | Blood Loss Amount | Plasmapheresis

Data type

boolean

Alias
UMLS CUI [1,1]
C0005841
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C0005794
UMLS CUI [2,2]
C1265611
UMLS CUI [3,1]
C3163616
UMLS CUI [3,2]
C1265611
UMLS CUI [4]
C0032134
9. subjects currently receiving a long acting esa, or who have received a long acting esa in the 16 weeks prior to study randomization.
Description

Erythropoiesis Stimulating Agents Active Long-term

Data type

boolean

Alias
UMLS CUI [1,1]
C1959590
UMLS CUI [1,2]
C0205177
UMLS CUI [1,3]
C0443252

Similar models

Eligibility Chronic Kidney Disease (CKD) NCT02504294

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
1. adult female or male subjects; age ≥18 years.
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Kidney Failure, Chronic | Hemodialysis
Item
2. end stage renal disease subjects treated in-center with the modality of hemodialysis for ≥120 days.
boolean
C0022661 (UMLS CUI [1])
C0019004 (UMLS CUI [2])
Anemia
Item
3. diagnosed with anemia.
boolean
C0002871 (UMLS CUI [1])
Epogen Intravenous | Anemia | Unit dose Algorithm Erythropoiesis Stimulating Agents
Item
4. administered routine epogen therapy for at least 16 weeks by an iv route for treatment of anemia using the epogen version of the fresenius medical care north america (fmcna) dosing algorithm for esa.
boolean
C0700704 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C0002871 (UMLS CUI [2])
C0869039 (UMLS CUI [3,1])
C0002045 (UMLS CUI [3,2])
C1959590 (UMLS CUI [3,3])
Epogen Intravenous | Unit dose Algorithm Erythropoiesis Stimulating Agents | Anemia Management
Item
5. currently using the iv epogen version of the esa dosing algorithm cmab 5 for anemia management.
boolean
C0700704 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
C0869039 (UMLS CUI [2,1])
C0002045 (UMLS CUI [2,2])
C1959590 (UMLS CUI [2,3])
C0002871 (UMLS CUI [3,1])
C0376636 (UMLS CUI [3,2])
Hemodialysis | Iron replacement Intravenous | Unit dose Algorithm
Item
6. receiving hemodialysis at a clinic using the fmcna dosing algorithm for iv iron that is the fmcna standard of care for iron replacement.
boolean
C0019004 (UMLS CUI [1])
C0919650 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C0869039 (UMLS CUI [3,1])
C0002045 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Informed Consent Unable
Item
1. subjects unable to provide a signed and dated informed consent for this clinical research study.
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Childbearing Potential Contraceptive methods Unwilling
Item
2. as determined by the investigator, female subjects of childbearing potential who do not agree to use a highly effective method of contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Condition Study Subject Participation Status At risk | Condition Excludes Protocol Compliance
Item
3. any condition as determined by the investigator that would place a subject at an increased risk, or preclude subject's full compliance with the study procedures and visits.
boolean
C0348080 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
C0525058 (UMLS CUI [2,3])
Pregnancy | Breast Feeding
Item
4. female subjects who are known to be or found to be, pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Inappropriate Erythropoiesis Stimulating Agents | Epogen Package Inserts | Other Coding | Recombinant Erythropoietin Antibodies Positive
Item
5. subjects that are not a candidate for esa therapies per the label warnings listed in the package insert for epogen and/or contraindications to epoetin hospira listed in the investigators' brochure; or have had a known positive test for anti-rhepo antibodies.
boolean
C0681850 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C1959590 (UMLS CUI [1,3])
C0700704 (UMLS CUI [2,1])
C0030174 (UMLS CUI [2,2])
C3846158 (UMLS CUI [3])
C0376541 (UMLS CUI [4,1])
C0003241 (UMLS CUI [4,2])
C1514241 (UMLS CUI [4,3])
Investigational New Drugs
Item
6. treatment with any investigational drug within 30 days prior to randomization and throughout this clinical trial.
boolean
C0013230 (UMLS CUI [1])
Condition Resulting in Blood Loss | Menorrhagia | Peptic Ulcer | Gastrointestinal Hemorrhage | Hematological Disease | Hemoglobinopathy | Anticoagulation Therapy | Exception Dialysis | Exception Aspirin therapy
Item
7. diagnosed with any concurrent condition that could lead to greater-than-normal loss of blood, including but not limited to menorrhagia, peptic ulcer disease, gastrointestinal bleeding, blood dyscrasia, hemoglobinopathy, anticoagulation therapy (except when administered for the purpose of dialysis therapy and except aspirin (acetylsalicylic acid [asa] therapies)) etc.
boolean
C0348080 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C3163616 (UMLS CUI [1,3])
C0025323 (UMLS CUI [2])
C0030920 (UMLS CUI [3])
C0017181 (UMLS CUI [4])
C0018939 (UMLS CUI [5])
C0019045 (UMLS CUI [6])
C0003281 (UMLS CUI [7])
C1705847 (UMLS CUI [8,1])
C0011946 (UMLS CUI [8,2])
C1705847 (UMLS CUI [9,1])
C4303556 (UMLS CUI [9,2])
Blood Transfusion Quantity | Blood Donation Amount | Blood Loss Amount | Plasmapheresis
Item
8. history of transfusion of any blood product in the past 3 months, or 2 or more transfusions in the past 1 year; or donated or lost >475 ml blood volume (including plasmapheresis) in the past 3 months.
boolean
C0005841 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0005794 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C3163616 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0032134 (UMLS CUI [4])
Erythropoiesis Stimulating Agents Active Long-term
Item
9. subjects currently receiving a long acting esa, or who have received a long acting esa in the 16 weeks prior to study randomization.
boolean
C1959590 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0443252 (UMLS CUI [1,3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial